19 results
8-K
EX-99.2
KA
Kineta Inc
12 Mar 24
Partial response and stable disease reported in combination cohort, and durable stable disease observed in monotherapy cohorts
8:05am
(0) 2 (40) 7 (26) VISTA-101: Demographics As of 02/27/24
VISTA-101: KVA12123 was well tolerated in 3, 10, 30, 100 and 300mg monotherapy cohorts
8-K
EX-99.1
KA
Kineta Inc
5 Jan 24
Regulation FD Disclosure
4:30pm
Antineoplastic surgery 11 (73) 15 (100) 13 (87) Baseline ECOG N (%) Grade 0 Grade 1 3 (20) 12 (80) Demographics Stage and prior treatments Patients
8-K
EX-99.2
KA
Kineta Inc
6 Nov 23
Kineta Unveils Positive New Data from VISTA-101 Clinical Trial of KVA12123 at the Society for Immunotherapy of Cancer’s (SITC) 38th Annual Meeting
8:30am
Antineoplastic medication Antineoplastic surgery 9 (82) 11 (100) 11 (100) Baseline ECOG N (%) Grade 0 Grade 1 2 (18) 9 (82) Demographics Stage and prior
8-K
EX-99.1
KA
Kineta Inc
10 Nov 21
Regulation FD Disclosure
7:12am
occurred in the study 20
Patient Baseline Characteristics Variable Placebo (n=4) YTX-7739 (n=16) Demographics Males/Females Mean Age (min-max) Mean
8-K
EX-99.1
KA
Kineta Inc
5 Mar 20
Regulation FD Disclosure
4:30pm
(12.0) 62.8 (7.9) Baseline Demographics and Clinical Characteristics of F508del Homozygous and Heterozygous Study Cohorts 7
F508del Homozygous F508del
8-K
EX-99.2
bpflrclfghhmp6z6q td
22 Jan 20
Proteostasis Therapeutics Announces Keystone Symposia Presentation of
7:00am
8-K
EX-99.2
d42g8
17 Dec 19
Proteostasis Therapeutics Announces Positive Phase 2 Topline Results from Proprietary CFTR
8:30am
8-K
EX-99.1
78f418 fp
4 Dec 19
Regulation FD Disclosure
8:10am
8-K
EX-99.1
73eiz
1 Nov 19
Regulation FD Disclosure
8:00am
8-K
EX-99.1
jby 2fcsj
3 Oct 19
Regulation FD Disclosure
8:01am
8-K
EX-99.1
i23edc 731mxiv707h
5 Aug 19
Regulation FD Disclosure
5:20pm
8-K/A
EX-99.1
t5mu5xirqxyzb3y2y
13 May 19
Departure of Directors or Certain Officers
5:28pm
8-K
EX-99.1
5ugq3t 4h
13 May 19
Departure of Directors or Certain Officers
8:00am
8-K
EX-99.1
fvo1v4r
7 Jan 19
Departure of Directors or Certain Officers
7:31am
8-K
EX-99.1
36yav1ejznv67bq7z
28 Nov 18
Regulation FD Disclosure
8:00am
8-K
EX-99.2
b13dta89 kuu7
17 Oct 18
Proteostasis Therapeutics Announces Positive Preliminary Results from
4:30pm
8-K
EX-99.1
n6q k35ygyrxz91
3 Oct 18
Regulation FD Disclosure
8:01am
8-K
EX-99.1
hdnbdaz3efffq6j
26 Jul 18
Regulation FD Disclosure
7:59am
8-K
EX-99.2
n4v9sd7u
6 Jun 18
Proteostasis Announces Positive Data from Ongoing Phase 1 Study ofPTI-801 in Cystic Fibrosis Patients on Background Orkambi® Therapy
4:11pm
- Prev
- 1
- Next